ARAMCO-DIGITAL
15.1.2024 14:33:31 CET | Business Wire | Press release
Aramco Digital and Intel announced their intent to establish Saudi Arabia’s inaugural Open RAN (Radio Access Network) Development Center. The facility is expected to drive innovation, foster technological advancements and contribute to the digital transformation landscape in the Kingdom.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240115542031/en/
The collaborative effort aims to accelerate the development and deployment of Open RAN technologies, helping to enable the Kingdom to build robust and agile telecommunication infrastructure focused on accelerating digitization across industries. This collaboration aims to align with Saudi Arabia's Vision 2030, which focuses on technological advancements and economic diversification.
Open RAN, an evolving paradigm in wireless network architecture, allows for greater flexibility, interoperability and innovation. Aramco Digital brings a deep understanding of the development needs and ambitions of the Kingdom and the opportunities for Open RAN technology deployment, along with a unique perspective of the Kingdom's economic landscape. Intel, a pioneer in computing and communication technologies, brings its expertise in Open RAN technologies to the collaboration.
Highlights of the collaboration:
1. **Innovation Hub:** The Open RAN Development Center aims to serve as an innovation hub, fostering collaboration between Aramco Digital and Intel engineers, researchers and industry experts.
2. **Local Talent Development:** The Center aims to contribute to the development of local talent by providing training and hands-on experience in the rapidly evolving field of Open RAN and Edge computing technology.
3. **Economic Impact:** The collaboration aims to contribute to the local economy through technology-driven initiatives, aligning with the broader objectives of Vision 2030.
4. **Global Collaboration:** The collaboration on Open RAN between Aramco Digital and Intel is expected to extend beyond borders, connecting Saudi Arabia to the global landscape of Open RAN and Edge development and deployment.
Aramco Digital's CEO Tareq Amin said: "This collaboration is a testament to our commitment to helping drive innovation in the Kingdom. The Open RAN Development Center is expected to be a catalyst for digital evolution, providing a platform for collaboration, skill development and the creation of a vibrant technology ecosystem. At the heart of this collaboration is the creation of a vibrant pool of local capabilities for advanced 5G and future 6G technologies.”
"We are pleased to collaborate on Open RAN with Aramco Digital and to combine Intel's technological prowess in network and edge computing and software with the local insights and industry leadership of Aramco Digital. Together, we aim to accelerate the deployment of edge-native Open RAN solutions in Saudi Arabia and beyond," said [Sachin Katti, Intel senior vice president and general manager of the Network and Edge Group].
The Open RAN Development Center is planned to commence operations in 2024, marking a milestone in Saudi Arabia's journey towards a technology-driven future.
About Aramco Digital:
Aramco Digital is the digital and technology subsidiary of Aramco, a global integrated energy and chemicals company. Aramco Digital aims to help drive digital transformation and technological innovation across various sectors.
About Intel:
Intel (NASDAQ: INTC) is a world leader in computing innovation. The company designs and builds the essential technologies that serve as the foundation for the world's computing devices.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240115542031/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom